1. Lipid inclusions in cardiac myocytes โ a rare case of cardiolipotoxicity
- Author
-
Saikrishna Patibandla, John T. Fallon, Purva Ranchal, Rahul Gupta, Gregg M. Lanier, Rugved Pattarkine, and Sugandhi Mahajan
- Subjects
Male ,medicine.medical_specialty ,Cardiomyopathy ,Infarction ,030204 cardiovascular system & hematology ,Ventricular tachycardia ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,Fibrosis ,Internal medicine ,medicine ,Humans ,Myocyte ,Myocytes, Cardiac ,Obesity ,Aged ,Heart Failure ,business.industry ,Myocardium ,Restrictive cardiomyopathy ,medicine.disease ,Lipids ,Lipotoxicity ,Heart failure ,Cardiology ,Molecular Medicine ,Cardiology and Cardiovascular Medicine ,business - Abstract
The heart oxidizes fatty acids for its energy production. The physiological balance between fatty acid uptake and its oxidation prevents lipid accumulation in cardiac myocytes. However, accumulation of lipids due to various processes such as obesity, diabetes, heart failure, myocardial ischemia or infarction can result in damage to the heart tissue, also known as cardiolipotoxicity. We present a unique case of a 69-year-old gentleman with a history of heart failure and ventricular tachycardia. Endomyocardial biopsy to assess for restrictive cardiomyopathy/amyloid showed no evidence of amyloid, significant inflammation or fibrosis, but did show intracellular accumulation of significant amorphous material in most cardiac myocytes. We review the literature regarding the pathogenesis of cardiolipotoxicity, which has no definite cause or treatment yet identified.
- Published
- 2021
- Full Text
- View/download PDF